Switch theme
Sign up to access all valuation multiples
Medika DD operates in the medical distribution industry in Croatia. The company is engaged in the sale and distribution of pharmaceuticals, healthcare facilities, hospitals, health centers, clinics, surgeries, wholesalers, and specialized stores.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medika has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Medika achieved revenue of $844M and an EBITDA of $34.2M.
Medika expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medika valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $687M | $844M | XXX | XXX | XXX |
| Gross Profit | $48.2M | $53.3M | XXX | XXX | XXX |
| Gross Margin | 7% | 6% | XXX | XXX | XXX |
| EBITDA | $27.4M | $34.2M | XXX | XXX | XXX |
| EBITDA Margin | 4% | 4% | XXX | XXX | XXX |
| Net Profit | $14.6M | $17.0M | XXX | XXX | XXX |
| Net Margin | 2% | 2% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 13, 2025, Medika's stock price is EUR 5250 (or $5906).
Medika has current market cap of EUR 152M (or $171M), and EV of EUR 205M (or $231M).
See Medika trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $231M | $171M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 13, 2025, Medika has market cap of $171M and EV of $231M.
Medika's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Medika's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Medika and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $231M | XXX | XXX | XXX |
| EV/Revenue | 0.3x | XXX | XXX | XXX |
| EV/EBITDA | 6.7x | XXX | XXX | XXX |
| P/E | 7.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 11.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedika's NTM/LTM revenue growth is n/a
Medika's revenue per employee for the last fiscal year averaged $1.6M, while opex per employee averaged n/a for the same period.
Over next 12 months, Medika's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Medika's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Medika and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | XXX | XXX | XXX |
| EBITDA Margin | N/A | XXX | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | N/A | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.6M | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 0% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medika acquired XXX companies to date.
Last acquisition by Medika was XXXXXXXX, XXXXX XXXXX XXXXXX . Medika acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Medika founded? | Medika was founded in 1922. |
| Where is Medika headquartered? | Medika is headquartered in Croatia. |
| How many employees does Medika have? | As of today, Medika has 533 employees. |
| Is Medika publicy listed? | Yes, Medika is a public company listed on ZAG. |
| What is the stock symbol of Medika? | Medika trades under MDKA ticker. |
| When did Medika go public? | Medika went public in 2005. |
| Who are competitors of Medika? | Similar companies to Medika include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Medika? | Medika's current market cap is $171M |
| What is the current revenue growth of Medika? | Medika revenue growth between 2023 and 2024 was 23%. |
| Is Medika profitable? | Yes, Medika is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
